808140-97-8 Usage
Uses
Used in Pharmaceutical Development:
(3-cyclopropoxyphenyl)boronic acid is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its ability to form stable complexes with diols allows for the creation of new molecules with potential therapeutic properties.
Used in Agrochemicals:
In the agrochemical industry, (3-cyclopropoxyphenyl)boronic acid is used as a starting material for the development of novel compounds with pesticidal or herbicidal activities. Its unique reactivity can be harnessed to design molecules that target specific pests or weeds, increasing the efficiency and selectivity of these chemicals.
Used in Materials Science:
(3-cyclopropoxyphenyl)boronic acid is utilized as a building block in the synthesis of new materials with specialized properties. Its incorporation into polymers or other materials can lead to enhanced mechanical, thermal, or electrical characteristics, depending on the desired application.
Used in Organic Synthesis:
As a boronic acid derivative, (3-cyclopropoxyphenyl)boronic acid is used as a reagent in organic synthesis to facilitate a range of chemical reactions. Its compatibility with diols makes it a useful component in the formation of new carbon-carbon or carbon-heteroatom bonds, which are essential in constructing complex molecular structures.
Check Digit Verification of cas no
The CAS Registry Mumber 808140-97-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,0,8,1,4 and 0 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 808140-97:
(8*8)+(7*0)+(6*8)+(5*1)+(4*4)+(3*0)+(2*9)+(1*7)=158
158 % 10 = 8
So 808140-97-8 is a valid CAS Registry Number.
808140-97-8Relevant academic research and scientific papers
AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS
-
Page/Page column 55, (2009/04/25)
New azabiphenylaminobenzoic acid derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH)
